Thrombosis in cancer: Research priorities identified by a national cancer institute/national heart, lung, and blood institute strategic working group

Cancer Research

Volumn 76, Issue 13, 2016, Pages 3671-3675

  Key, Nigel S ^a   Khorana, Alok A ^b   Mackman, Nigel ^a   McCarty, Owen J T ^c   White, Gilbert C ^d   Francis, Charles W ^e   McCrae, Keith R ^b,f   Palumbo, Joseph S ^g   Raskob, Gary E ^h   Chan, Andrew T ⁱ   Sood, Anil K ^j  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BIOLOGICAL MARKER; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NUCLEIC ACID BINDING PROTEIN;

CANCER RESEARCH; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DISEASE ASSOCIATION; EXTRACELLULAR TRAP; HEMOSTASIS; HUMAN; INCIDENCE; INFLAMMATION; NEOPLASM; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE; THROMBOCYTOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; COMPLICATION; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; PROCEDURES; RESEARCH; THROMBOSIS; UNITED STATES;

BIOMEDICAL RESEARCH; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); NEOPLASMS; RESEARCH REPORT; THROMBOSIS; UNITED STATES;

EID: 84977522286     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3100     Document Type: Conference Paper

References (36)

1. ISTH Steering Committee for World Thrombosis Day. Thrombosis: amajor contributor to the global disease burden. J Thromb Haemost 2014;12: 1580-90.
2. Marks MA, Engels EA. Venous thromboembolism and cancer risk among elderly adults in the United States. Cancer Epidemiol Biomarkers Prev 2014;23:774-83.
3. Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011;9:653-63.
4. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914-8.
5. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-300.
6. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008;8:1247-55.
7. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-8.
8. Digklia A, Voutsadakis IA. Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer. Obstet Gynecol Sci 2014;57: 457-63.
9. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is themain source of TF activity released from human cancer cells. J Thromb Haemost 2004;2:2065-7.
10. Davila M, Robles-Carrillo L, Unruh D, Huo Q, Gardiner C, Sargent IL, et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation? J Thromb Haemost 2014;12:186-96.
11. Owens AP, 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011;108:1284-97.
12. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013;122:1873-80.
13. Phillips KG, Lee AM, Tormoen GW, Rigg RA, Kolatkar A, Luttgen M, et al. The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. Am J Physiol Cell Physiol 2015;308:C229-36.
14. Hu B, Goldkorn A. Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther 2014;14:1257-60.
15. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6:401-10.
16. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 2011;9:2313-21.
17. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5.
18. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr., et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010;107:15880-5.
19. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1777-83.
20. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012;97:1158-64.
21. Thaler J, Ay C, Mackman N, Bertina RM, Kaider A, Marosi C, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012;10:1363-70.
22. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89-95.
23. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997;84:1099-103.
24. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-80.
25. Lee AY. Evidence-based medicine for thromboprophylaxis in hospitalized patients with cancer: why aren't we there yet? J Clin Oncol 2014;32:1754-6.
26. Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 2014;127:82-6 e1.
27. Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 2007;356: 1438-44.
28. Kuderer NM, Lyman GH. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res 2014;133 Suppl 2:S122-7.
29. Connors JM. Prophylaxis against venous thromboembolism in patients with cancer. N Engl J Med 2014;371:1263-4.
30. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7.
31. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377-82.
32. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17-21.
33. Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, et al. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013;13:284.
34. EINSTEIN-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366: 1287-97.
35. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
36. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.